{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:30:31Z","timestamp":1792524631531,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100002245","name":"National Down Syndrome Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Recent innovations in Alzheimer's disease (AD) treatment highlight critical gaps in knowledge about how to support healthy aging of adults with Down syndrome (DS). RAND researchers updated demographic and epidemiological evidence about the DS population to assess the impact of increased investment in treatment innovations for DS\u2010associated Alzheimer's disease (DS\u2010AD). They estimated life expectancy at birth in 2020 to be 55 years, with \u2248 5 years of DS\u2010AD. They found that the results of investment were dramatic. Between 2020 and 2070, adult years of life are expected to increase by 5 years without any increase in unhealthy years of life with DS\u2010AD. Caregiving hours for individuals with DS\u2010AD are expected to be reduced by 40%, which will generate large annual savings. The new evidence underscores the magnitude of the impact that investment in DS\u2010AD treatments could have for individuals with DS, their families, and caregivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Evidence is sparse about treatment for Down syndrome (DS)\u2010associated Alzheimer's disease (DS\u2010AD) and healthy aging of DS adults.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This population simulation model estimates DS\u2010AD caregiving costs at \u2248 $1 billion per year.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>DS\u2010AD innovations could increase life expectancy by 5 years and reduce caregiving by 40% by 2070.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This better forecasting can improve policy and service planning.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>DS\u2010AD research investment could yield dramatic gains for individuals and families.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.70348","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:00:21Z","timestamp":1757502021000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investment in Alzheimer's disease research for the next generation of adults with Down syndrome will yield health benefits for future generations"],"prefix":"10.1002","volume":"21","author":[{"given":"Margaret M.","family":"Weden","sequence":"first","affiliation":[{"name":"RAND Corporation  Santa Monica California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Frank","sequence":"additional","affiliation":[{"name":"National Alliance for Caregiving  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Dick","sequence":"additional","affiliation":[{"name":"RAND Corporation  Santa Monica California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zetianyu","family":"Wang","sequence":"additional","affiliation":[{"name":"RAND Corporation  Santa Monica California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Peschin","sequence":"additional","affiliation":[{"name":"Alliance for Aging Research  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Bovenkamp","sequence":"additional","affiliation":[{"name":"BrightFocus Foundation  Clarksburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharyn L.","family":"Rossi","sequence":"additional","affiliation":[{"name":"BrightFocus Foundation  Clarksburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Sciullo","sequence":"additional","affiliation":[{"name":"National Down Syndrome Society  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampus","family":"Hillerstrom","sequence":"additional","affiliation":[{"name":"LuMind IDSC Foundation  Woburn Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Fisher","sequence":"additional","affiliation":[{"name":"LuMind IDSC Foundation  Woburn Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"US Food and Drug Administration.FDA news release: FDA converts novel Alzheimer's disease treatment to traditional approval.2023;https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010converts\u2010novel\u2010alzheimers\u2010disease\u2010treatment\u2010traditional\u2010approval"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-230130"},{"key":"e_1_2_5_4_1","article-title":"People with Down syndrome deserve access to Alzheimer's treatment","author":"Hillerstrom H","year":"2018","journal-title":"The Boston Globe"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07142-1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13778"},{"key":"e_1_2_5_7_1","unstructured":"HillerstromH FisherR JanickiMP The Working Group on Criteria for Access to Alzheimer's Therapeutics for Adults with Down Syndrome.Adapting eligibility criteria for prescribing FDA approved anti\u2010amyloid immunotherapeutics for adults with Down syndrome with early stage Alzheimer's dementia. Lumind IDSC and the National Task Group.2023.https:\/\/lumindidsc.org\/wp\u2010content\/uploads\/2023\/06\/Working\u2010Group\u2010DS\u2010AD\u2010Eligibility\u2010Criteria\u2010May\u201030\u20102023.pdf"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X211016810"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12362"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.23.100901.140525"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.88.9.1337"},{"key":"e_1_2_5_13_1","volume-title":"Modeling the Impact of Research Investment on Down Syndrome \u2013 Associated Alzheimer's Disease (RRA2663)","author":"Weden MM","year":"2023"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12910"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.127"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3666"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12084"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132966"},{"key":"e_1_2_5_19_1","unstructured":"BellFC MillerML.Life tables for the United States Social Security Area 1900\u20102100. Social Security Administration Office of the Chief Actuary 2005."},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1471301205055028"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.13431"},{"issue":"1","key":"e_1_2_5_22_1","first-page":"26","article-title":"Caregiving and adults with intellectual disabilities affected by dementia","volume":"7","author":"Courtenay K","year":"2010","journal-title":"J Policy Pract Intel"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jir.12074"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70348","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.70348","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T11:07:09Z","timestamp":1771153629000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/alz.70348"],"URL":"https:\/\/doi.org\/10.1002\/alz.70348","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2024-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70348"}}